de la Rubia, J.; Alonso, R.; Clavero, M.E.; Askari, E.; GarcÃa, A.; Antón, C.; Fernández, M.; Escalante, F.; GarcÃa, A.; Rios-Tamayo, R.;
et al. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain. Cancers 2023, 15, 2964.
https://doi.org/10.3390/cancers15112964
AMA Style
de la Rubia J, Alonso R, Clavero ME, Askari E, GarcÃa A, Antón C, Fernández M, Escalante F, GarcÃa A, Rios-Tamayo R,
et al. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain. Cancers. 2023; 15(11):2964.
https://doi.org/10.3390/cancers15112964
Chicago/Turabian Style
de la Rubia, Javier, Rafael Alonso, MarÃa Esther Clavero, Elham Askari, Alfonso GarcÃa, Cristina Antón, Margarita Fernández, Fernando Escalante, Ana GarcÃa, Rafael Rios-Tamayo,
and et al. 2023. "Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain" Cancers 15, no. 11: 2964.
https://doi.org/10.3390/cancers15112964
APA Style
de la Rubia, J., Alonso, R., Clavero, M. E., Askari, E., GarcÃa, A., Antón, C., Fernández, M., Escalante, F., GarcÃa, A., Rios-Tamayo, R., Conesa, V., Bermúdez, M. A., Merchán, B., Velasco, A. E., Blanchard, M. J., Sampol, A., Gainza, E., Hernández, P. M., & Alegre, A.
(2023). Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain. Cancers, 15(11), 2964.
https://doi.org/10.3390/cancers15112964